Experts from Stoke are consulted for input to inform news coverage about our innovative science, the serious diseases we are working to address, and the industry we are proud to be a part of.
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)